Aroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product

MT Newswires Live2024-12-23

Aroa Biosurgery (ASX:ARX) said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.

The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.

The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.

Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.

The company's shares gained close to 2% in recent Monday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2493135277?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-23 09:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2493135277","market":"sg","top_or_hot":-1,"title":"Aroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product","media":"MT Newswires Live","content":"<html><body><p> Aroa Biosurgery (ASX:ARX) said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.</p><p>The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.</p><p>The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.</p><p>Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.</p><p>The company's shares gained close to 2% in recent Monday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Aroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAroa Biosurgery Says Real-World Study Backs Efficacy of Regenerative Product\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-23 09:50 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Aroa Biosurgery (ASX:ARX) said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.The ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2493135277","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2493135277","pubTimestamp":1734918617,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Aroa Biosurgery  said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.The company's shares gained close to 2% in recent Monday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","ARX.AU":"AROA BIOSURGERY LTD"},"translate_title":"Aroa Biosurgery表示现实世界研究支持再生产品的功效","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARX.AU":0.9},"content_text":"Aroa Biosurgery (ASX:ARX) said a real-world study showed the efficacy of its Myriad product designed for limb reconstruction procedures, according to a Monday filing with the Australian bourse.The study, conducted in patients with high risks of complications and amputations, showed that the Myriad Matrix and Myriad Morcells regenerative products were able to achieve full coverage with no infections and complications, the filing said.The study covered 120 patients with 130 lower limb defects, the filing said. Across all participants, 95% had at least one risk factor for amputation, and 55% had three or more risk factors.Results were published in the peer-reviewed journal Plastic and Reconstructive Surgery - Global Open.The company's shares gained close to 2% in recent Monday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2493135277"}